Paratek Pharmaceuticals Inc (NASDAQ:PRTK) VP William M. Haskel sold 4,132 shares of the company’s stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $6.64, for a total value of $27,436.48. Following the completion of the transaction, the vice president now directly owns 131,775 shares of the company’s stock, valued at approximately $874,986. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of PRTK traded down $0.25 during mid-day trading on Friday, reaching $6.01. The company had a trading volume of 635,065 shares, compared to its average volume of 250,043. Paratek Pharmaceuticals Inc has a twelve month low of $5.94 and a twelve month high of $19.35. The company has a debt-to-equity ratio of 3.97, a current ratio of 11.39 and a quick ratio of 11.39.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.16). Paratek Pharmaceuticals had a negative return on equity of 132.55% and a negative net margin of 2,155.03%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $5.89 million. As a group, research analysts forecast that Paratek Pharmaceuticals Inc will post -3.47 earnings per share for the current year.

Several equities analysts have commented on the company. BidaskClub raised Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 6th. Bank of America assumed coverage on Paratek Pharmaceuticals in a report on Monday, August 27th. They issued a “neutral” rating and a $13.00 price target for the company. Guggenheim set a $26.00 price target on Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. ValuEngine raised Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, HC Wainwright cut their price target on Paratek Pharmaceuticals from $55.00 to $22.00 and set a “buy” rating for the company in a report on Friday, November 23rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $25.57.

Several institutional investors and hedge funds have recently modified their holdings of PRTK. Highland Capital Management LP raised its holdings in shares of Paratek Pharmaceuticals by 99.9% in the 2nd quarter. Highland Capital Management LP now owns 1,917,878 shares of the specialty pharmaceutical company’s stock worth $19,562,000 after buying an additional 958,600 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Paratek Pharmaceuticals by 27.3% in the 2nd quarter. BlackRock Inc. now owns 2,583,390 shares of the specialty pharmaceutical company’s stock worth $26,350,000 after buying an additional 554,545 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Paratek Pharmaceuticals in the 3rd quarter worth approximately $1,860,000. Granahan Investment Management Inc. MA acquired a new position in shares of Paratek Pharmaceuticals in the 2nd quarter worth approximately $1,801,000. Finally, Water Island Capital LLC raised its holdings in shares of Paratek Pharmaceuticals by 53.5% in the 3rd quarter. Water Island Capital LLC now owns 439,726 shares of the specialty pharmaceutical company’s stock worth $4,265,000 after buying an additional 153,226 shares in the last quarter. 74.75% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/12/16/paratek-pharmaceuticals-inc-prtk-vp-william-m-haskel-sells-4132-shares.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: Float

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.